Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
about
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabineOptimizing the management of advanced non-small-cell lung cancer: a personal viewChemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesIndividual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trialA randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.Gemcitabine for the treatment of advanced nonsmall cell lung cancerA phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancerPharmacogenomics: a reality or still a promise?Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.Gemcitabine (Gemzar) in non-small cell lung cancer.Paclitaxel for non-small cell lung cancer.Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).Role of gemcitabine in cancer therapy.Present and future of lung cancer vaccines.Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.Molecular predictors of chemotherapy response in non-small-cell lung cancer.Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality.Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.Emerging ethnic differences in lung cancer therapy.A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancerPhase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancersLessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.Refining the treatment of advanced nonsmall cell lung cancer.Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.Is gemcitabine cost effective in cancer treatment?A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.Effect of differential drying techniques on PLGA nanoparticles containing hydrophobic and hydrophilic anticancer agents.Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.Subjective sleep quality in lung cancer patients before and after chemotherapy.
P2860
Q24652443-17B407E5-1C32-4C45-BC70-34385C004488Q24656144-E1A301C7-8DC7-4C7E-94EE-439C0BDF6854Q24792196-DBF5FAC1-840B-44EB-9BDC-E018B3C5A334Q28074716-B939ABDD-DB04-40C6-89D6-5EFCB9B833C0Q30833179-4142D9AE-089D-406D-A05D-9EEFC41F6F34Q33266837-C0ADA284-1FA2-41D5-9A20-75D549B5D654Q33358448-FFAFDDA2-F041-40D4-9322-DFAFE654FF63Q33367325-D08D7C1F-2684-4463-B6AF-8BD090000120Q33446356-2D0BB226-67B7-4E18-82E3-C1CD99F70E55Q33751771-E634F595-9901-4042-AFCB-E141346BC863Q33813555-D03A01CF-83E7-4513-AC14-25575879DE82Q33915997-B361C166-1BDD-4A11-ADCF-0A0947569856Q33954561-20E286F8-419E-4221-A61C-232D619285A7Q35565186-33665A20-76E6-47CD-A60C-40958BDF7EB9Q35671440-A843FF0D-8FA4-4FC8-8F30-89F0695EE67EQ35782899-8D7E7205-E355-4786-9403-FEC8FE6363D0Q35841594-6B4EC20B-52B5-4A39-8D41-7A6E97361901Q35879879-96A948AA-AD9A-4243-BD3A-7A5B1224C7B1Q36429373-C4FD3126-AA63-40ED-B107-B4C94F18D5A3Q36580586-75D25729-F47F-4CEC-9B4A-C132D8EFA5B7Q36615385-8A8B40C8-6D73-420E-8765-2E9A2052CD51Q36671151-5AFC6C10-6560-4DA8-A7A4-BE7F1ED56CFDQ36788498-4C51299B-C68E-4C72-872D-97BB0E19A260Q36864786-09BA24C5-58DE-4B75-A2E2-68935078BB76Q36927640-B595B8A1-B0B9-4571-B612-6068EC8AB275Q36975137-6E3C8C95-BB14-4662-8645-8F443BFEE511Q37010547-91E48125-9938-43E3-9A9B-6438C80A5258Q37023671-A22B99E8-2511-4B31-A745-23364C7D1F7BQ37346454-898C2D70-8E66-43B6-B788-64A3D8E85B23Q37360492-6AC7C4B2-D12A-4140-9887-CC120A107E1FQ37645169-7A32085E-AFF8-4EE5-B3B2-02109D5292D3Q38032176-D7D96D39-848E-45D0-9341-78DCF0DEECB2Q38190461-FEE4EC82-810F-4EF0-A016-E3A8A6651F5BQ38742506-8DF70F85-ADFD-409C-BFBD-CAABD995BB21Q38852314-5230D3AD-13D3-44C4-B7B7-2EE2F9025899Q43042833-BDB357DF-350F-4EC5-9787-F72F3D1D86B3Q43260541-E0A35935-C51C-41F1-B14C-2DDD8D4F5670Q45969651-6D618DE5-F8F6-4D14-B55A-D29EA231A376Q46727665-1F335FD3-7BE8-414B-8CAC-FC952D58E051Q48180796-EA5B229F-1926-449B-BE57-8B5C2D49E21A
P2860
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@ast
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@en
type
label
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@ast
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@en
prefLabel
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@ast
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@en
P2093
P50
P356
P1476
Paclitaxel plus carboplatin ve ...... a phase III randomized trial.
@en
P2093
Charalabos Bacoyiannis
Charalabos Kalophonos
Costas Nicolaides
Dimitrios Tsavdaridis
Epaminontas Samantas
John Boukovinas
Nick Mylonakis
Paris Kosmidis
Pavlos Papakostas
Theophanis Economopoulos
P304
P356
10.1200/JCO.2002.12.112
P407
P577
2002-09-01T00:00:00Z